Apersys AG has developed a long-term organ perfusion platform that mimics physiological conditions to preserve and recover livers for transplantation. This technology addresses the critical issue of organ viability, enhancing the success rates of liver transplants and improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
The limited availability of viable donor livers for transplantation results in prolonged waiting times and increased mortality for patients with end-stage liver disease. Current preservation methods often fail to maintain optimal organ function, leading to graft failure and poor patient outcomes.
Solution
Apersys AG offers a long-term organ perfusion platform designed to mimic physiological conditions, thereby preserving and recovering livers for transplantation. The platform aims to improve organ viability by creating an environment that supports liver function outside the body. This technology has the potential to increase the number of livers available for transplant and improve the success rates of liver transplantation, ultimately enhancing patient outcomes.
Target Audience
The primary target audience includes transplant centers, hospitals, and research institutions involved in liver transplantation.
Features
- Organ perfusion platform that mimics physiological conditions
- Long-term preservation capabilities for donor livers
- Designed to recover livers initially deemed unsuitable for transplant